Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus

Covid-19 treatment update: follow the scientific evidence

“…fda.gov). There was an expectation that companies would increase production for the commercial market as well to avoid shortages for patients with autoimmune disease who rely on hydroxychloroquine sulfate (Plaquenil®) for routine treatment [4].…”

Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic

“…5,6 Concerns have been raised that the premature off-label use of CQ and HCQ in COVID-19 may result in shortages of these medicines in their established, approved indications (i.e., against autoimmune diseases and, in case of CQ, Plasmodium vivax malaria). 7,8 The demand for CQ and HCQ quickly outstripped the supply, exacerbating the risk of falsified medicines entering the market. 8 We here report the recent occurrence of falsified CQ, detected in Cameroon and the Democratic Republic (DR) of Congo.…”

Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review

“…These findings have implications for clinical practice and policy in the current pandemic. Despite the potential therapeutic effect of chloroquine and hydroxychloroquine, fears exist that excess demand may lead to a shortage for people with other diseases who are currently taking these drugs (19).…”

“…At this stage of the pandemic, it is difficult to debate the treatment options for COVID- 19. There are many ideas and theories being considered about this novel virus and currently clinicians lack the necessary evidence to effectively treat the infection.…”